Author | Périssé, André R. S. | |
Author | Smeaton, Laura | |
Author | Chen, Yun | |
Author | La Rosa, Alberto | |
Author | Walawander, Ann | |
Author | Nair, Apsara | |
Author | Grinsztejn, Beatriz | |
Author | Santos, Breno | |
Author | Kanyama, Cecilia | |
Author | Hakim, James | |
Author | Nyirenda, Mulinda | |
Author | Kumarasamy, Nagalingeswaran | |
Author | Lalloo, Umesh G. | |
Author | Flanigan, Timothy | |
Author | Campbell, Thomas B. | |
Author | Hughes, Michael D. | |
Access date | 2019-01-28T12:14:39Z | |
Available date | 2019-01-28T12:14:39Z | |
Document date | 2013 | |
Citation | PÉRISSÉ, André R. S. et al. Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease. Plos One, v. 8, n. 12, p. 1-7, Dec. 2013. | pt_BR |
ISSN | 1932-6203 | pt_BR |
URI | https://www.arca.fiocruz.br/handle/icict/31322 | |
Description | P E A R L S study team of the ACTG. | |
Sponsorship | The project described was supported by Award Numbers UMAI068634 and UMAI068636 from the National Institute of Allergy and Infectious Diseases and supported by National Institute of Mental Health (NIMH), National Institute of Dental and Craniofacial Research (NIDCR). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health. Bristol Myers Squibb provided atazanavir, didanosine-EC and efavirenz (with consent of Merck); Gilead Sciences, Inc. provided emtricitabine,
tenofovir-DF, emtricitabine/tenofovir-DF and financial support for purchase of other study drugs; GlaxoSmithKline provided lamivudine, zidovudine and lamivudine/zidovudine; and Boehringer Ingelheim Pharmaceuticals, Inc. provided nevirapine. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials. Employees of the NIAID participated as study team members and authors of this manuscript. The NIAID provided recommendations on the study design and approved the final study design, but had no role in data collection and analysis, decision to publish, or preparation of the manuscript. Bristol Myers Squibb, Gilead Sciences Inc., GlaxoSmithKline and Boehringer Ingelheim Pharmaceuticals, Inc. had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Representatives of the pharmaceutical company sponsors participated as study team members and authors of this manuscript, but did not participate in data collection, data analyses or interpretation. | |
Language | eng | pt_BR |
Publisher | Public Library of Science | pt_BR |
Rights | open access | pt_BR |
Title | Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease | pt_BR |
Type | Article | pt_BR |
DOI | 10.1371/journal.pone.0083643 | |
Abstract | Background: Tuberculosis (TB) is common among HIV-infected individuals in many resource-limited countries and has been associated with poor survival. We evaluated morbidity and mortality among individuals first starting antiretroviral therapy (ART) with concurrent active TB or other AIDS-defining disease using data from the "Prospective Evaluation of Antiretrovirals in Resource-Limited Settings" (PEARLS) study. Methods: PARTICIPANTS WERE CATEGORIZED RETROSPECTIVELY INTO THREE GROUPS ACCORDING TO PRESENCE OF ACTIVE CONFIRMED OR PRESUMPTIVE DISEASE AT ART INITIATION: those with pulmonary and/or extrapulmonary TB ("TB" group), those with other non-TB AIDS-defining disease ("other disease"), or those without concurrent TB or other AIDS-defining disease ("no disease"). Primary outcome was time to the first of virologic failure, HIV disease progression or death. Since the groups differed in characteristics, proportional hazard models were used to compare the hazard of the primary outcome among study groups, adjusting for age, sex, country, screening CD4 count, baseline viral load and ART regimen. Results: 31 of 102 participants (30%) in the "TB" group, 11 of 56 (20%) in the "other disease" group, and 287 of 1413 (20%) in the "no disease" group experienced a primary outcome event (p = 0.042). This difference reflected higher mortality in the TB group: 15 (15%), 0 (0%) and 41 (3%) participants died, respectively (p<0.001). The adjusted hazard ratio comparing the "TB" and "no disease" groups was 1.39 (95% confidence interval: 0.93-2.10; p = 0.11) for the primary outcome and 3.41 (1.72-6.75; p<0.001) for death. Conclusions: Active TB at ART initiation was associated with increased risk of mortality in HIV-1 infected patients. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Departamento de Ciências Biológicas. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Harvard School of Public Health. Center for Biostatistics in AIDS Research. Boston, MA, USA. | pt_BR |
Affilliation | Harvard School of Public Health. Center for Biostatistics in AIDS Research. Boston, MA, USA. | pt_BR |
Affilliation | Asociación Civil Impacta Salud y Educación. Lima, Peru. | pt_BR |
Affilliation | Frontier Science and Technology Research Foundation. Amherst, NY, USA. | pt_BR |
Affilliation | Frontier Science and Technology Research Foundation. Amherst, NY, USA. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brazil, | pt_BR |
Affilliation | Hospital Nossa Senhora da Conceição. Porto Alegre, RS, Brasil. | pt_BR |
Affilliation | Kamuzu Central Hospital. Lilongwe, Malawi. | pt_BR |
Affilliation | University of Zimbabwe College of Health Sciences. Harare, Zimbabwe. | pt_BR |
Affilliation | University of Malawi. College of Medicine. Blantyre, Malawi. | pt_BR |
Affilliation | YRG Centre for AIDS Research and Education. Chennai, India. | pt_BR |
Affilliation | Nelson R. Mandela School of Medicine. Durban, South Africa. | pt_BR |
Affilliation | Brown Medical School. Providence, RI, USA. | pt_BR |
Affilliation | University of Colorado. School of Medicine. Department of Medicine. Division of Infectious Diseases. Aurora, CO, USA. | pt_BR |
Affilliation | Harvard School of Public Health. Department of Biostatistics. Boston, MA, USA. | pt_BR |
Subject | HIV-1 | pt_BR |
Subject | Antiretroviral therapy | pt_BR |
Subject | Tuberculosis | pt_BR |
e-ISSN | 1932-6203 | |